The alliance combines Origenis’ compound design and synthesis capabilities with Alcon’s applied biology expertise, screening capabilities and development expertise.
Origenis will apply its technology platform MOREsystem to deliver preclinical candidates with indication optimized profiles against targets identified by Alcon.
Under the terms of the agreement, Alcon will retain the rights to any products for ophthalmic and nasal applications and Origenis will retain certain rights to all other uses of drug candidates discovered during the alliance.
Alcon will make research payments to Origenis through a series of development milestones and royalties on sales.
“We have been impressed with Origenis’ capabilities and performance since the commencement of our relationship and we look forward to continuing our successful relationship in the future,” said Dr Marty Wax, vice president of ophthalmology discovery research at Alcon.